Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

Table 2 Efficacy of direct-acting antivirals based, (peg)-interferon-free antiviral therapy in patients with hepatitis C virus-associated (de-) compensated cirrhosis in controlled, prospective trials

Ref.	Therapy regimen	Treatment duration (wk)	Genotype	n (all)	n (cirrhotic patients)	n (MELD > 16)	SVR12 % (all patients)
Abergel et al[17]	LDV/SOF	12	5	41	9	Not specified	39/41 (95%)
Afdhal et al[53] (ION-1)	LDV/SOF ± RBV	12-24	1	865	136	Not specified	849/865 (98%)
Afdhal et al[54] (ION-2)	LDV/SOF ± RBV	12-24	1	440	88	Not specified	427/440 (97%)
Bouliere et al[18] (SIRIUS)	LDV/SOF ± RBV	12-24	1	155	155	Not specified	149/154 (97%)
Charlton et al[19] (SOLAR-1)	LDV/SOF/RBV	12-24	1, 4	337	108	27	89/108 (82%)1
Curry et al[20] (ASTRAL-4)	VEL/SOF ± RBV	12-24	1, 2, 3, 4, 6	267	267	13	234/267 (88%)
Curry et al[21]	SOF/RBV	Up to 48	1, 2, 3, 4	61	61	None	30/43 (70%)
Feld et al[22] (ASTRAL-1)	VEL/SOF	12	1, 2, 4, 5, 6	7412	142	Not specified	618/624 (99%)3
Feld et al[23] (TURQUOISE-III)	OBV/PTV/r + DSV	12	1b	60	60	Not specified	60/60 (100%)
Forns et al[24] (C-SALVAGE)	Grazoprevir/Elbasvir/RBV	12	1	79	34	Not specified	76/79 (96%)
Foster et al[25] (ASTRAL-2/-3)	VEL/SOF vs SOF/RBV	12	2, 3	818	201	Not specified	742/818 (91%)
Foster et al[68] (BOSON)	SOF/RBV ± IFN	12-24	2, 3	592	219	Not specified	494/592 (83%)
Kumada et al[26] (GIFT-1)	OBV/PTV/r	12	1b	363	42	Not specified	346/363 (95%)
Lawitz et al[27] (OPTIMIST-2)	SMV/SOF	12	1	103	103	Not specified	86/103 (83%)
Lawitz et al[28] (C-WORTHY)	Grazoprevir/Elbasvir ± RBV	12-18	1	253	170	Not specified	240/253 (95%)
Lawitz et al[29] (PEARL-I)	OBV/PTV/r + DSV	12-24	1	181	99	Not specified	172/181 (95%)
Leroy et al[30] (ALLY-3+)	DCV/SOF/RBV	12-16	3	50	50	Not specified	45/50 (90%)
Manns et al[31] (SOLAR-2)	LDV/SOF/RBV	12	1, 4	328	1604	41	121/140 (86%)
Mizokami et al[32]	LDV/SOF ± RBV	12	1	341	76	Not specified	338/341 (99%)
Nelson et al[33] (ALLY-3)	DCV/SOF	12	3	152	32	Not specified	135/152 (89%)
Omata et al[34]	SOF/RBV	12	2	153	17	Not specified	148/153 (97%)
Poordad et al[35] (TURQUOISE-II)	OBV/PTV/r + DSV/RBV	12-24	1	380	380	Not specified5	356/380 (94%)
Poordad et al[36] (ALLY-1)	DCV/SOF/RBV	12	1, 2, 3, 4, 6	1136	60	Not specified (CPT C 16)	100/113 (89%)7
Poordad et al[37] (QUARTZ-I)	OBV/PTV/r + DSV + SOF + RBV	12-24	1	22	7	Not specified	14/15 (93%)8
Wyles et al[38]	LDV/SOF/RBV	12	1	51	14	Not specified	50/51 (98%)
Zeuzem et al[39] (VALENCE)	SOF/RBV	12-24	2, 3	419	90	Not specified	302/334 (90%)9
Zeuzem et al[40] (C-EDGE)	Grazoprevir/elbasvir	12	1, 4, 6	421	92	Not specified	299/316 (95%)10

¹Only pretransplant cohort;

²116 patients received placebo;

³SVR in patients with compensated cirrhosis 99%;

⁴Patients with CPT class B or C cirrhosis pre- and posttranplant, additionally CPT class A patients posttransplant participated in this trial, the number was not specified;

⁵Only patients with CPT class A cirrhosis included;

⁶Only patients who had undetectable HCV-RNA at transplant were included in efficacy analysis;

⁷83% in the advanced cirrhosis cohort;

⁸Not all patients completed follow up until conference;

⁹85 patients received placebo;

¹⁰105 patients had deferred therapy. CPT: Child-Pugh-Turcotte; DAA: Direct-acting antivirals; DCV: Daclatasvir; DSV: Dasabuvir; LDV: Ledipasvir; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; PTV/r: Paritaprevir/ritonavir; VEL: Velpatasvir; SVR₁₂: Sustained virologic response 12 wk after end of treatment.